Cell & Gene Therapy Congress

Across two days, the programme focuses on real-world progress in gene and cell therapy development, featuring scientific and practical perspectives spanning modality innovation, disease-focused advances, and the hurdles that can slow clinical translation. The event is positioned as an open-access forum designed to connect the community and encourage collaboration around solutions that move advanced therapies forward.

Who the audience is and how many attend

Audience

• Academic and industry scientists working in cell and gene therapy discovery and translational research
• Clinicians, healthcare stakeholders and translational teams supporting movement into the clinic
• Start-ups, biotech leaders and business development professionals in advanced therapies
• Investors and enabling-technology providers across the CGT ecosystem

Scale

• ELRIG positions its conferences as open-access and free to attend, with dedicated exhibitor/sponsor involvement.
• The organiser does not consistently publish a single headline figure for total attendees, exhibitors/vendors, or main sponsors on the main event pages.

What to expect

• Two days of content focused on practical pathways to clinical translation in cell and gene therapy
• Disease- and modality-oriented sessions (including gene therapy for neurological/neurometabolic disorders and platform approaches for rare diseases)
• Networking across academia, biotech, investors and solution providers in a collaborative setting
• An in-person meeting at the Wellcome Genome Campus designed to support community-building and partnership conversations

Latest Features